Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis

Journal of Hepatology

Volumn 65, Issue 3, 2016, Pages 589-600

  Targher, Giovanni ^a   Byrne, Christopher D ^b,c   Lonardo, Amedeo ^d   Zoppini, Giacomo ^a   Barbui, Corrado ^e  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY OF VERONA   (Italy)

Author keywords

Cardiovascular disease; CVD events; Meta analysis; Mortality; NAFLD

Indexed keywords

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOGRAPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SYSTEMATIC REVIEW; META ANALYSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84991083809     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.013     Document Type: Article

References (56)

1. [1] Rinella, M.E., Non-alcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
2. [2] Non-alcoholic fatty liver disease (NAFLD) study group, dedicated to the memory of Prof. Paola Loria, Lonardo, A., Bellentani, S., Argo, C.K., et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 47 (2015), 997–1006.
3. [3] Anstee, Q.M., Targher, G., Day, C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10 (2013), 330–344.
4. [4] G. Targher, C.P. Day, Bonora, E., Risk of cardiovascular disease in patients with non-alcoholic fatty liver disease. N Engl J Med 363 (2010), 1341–1350.
5. [5] Byrne, C.D., Targher, G., NAFLD: a multisystem disease. J Hepatol 62 (2015), S47–S64.
6. [6] Ballestri, S., Lonardo, A., Bonapace, S., et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol 20 (2014), 1724–1745.
7. [7] Ballestri, S., Zona, S., Targher, G., et al. Non-alcoholic fatty liver disease is associated with an almost two-fold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 31 (2016), 936–944.
8. [8] Oni, E.T., Agatston, A.S., Blaha, M.J., et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with non-alcoholic fatty liver; should we care?. Atherosclerosis 230 (2013), 258–267.
9. [9] Puchner, S.B., Lu, M.T., Mayrhofer, T., et al. High-risk coronary plaque at coronary CT angiography is associated with non-alcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology 274 (2015), 693–701.
10. [10] Lonardo, A., Sookoian, S., Pirola, C.J., et al. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism, 2015, 10.1016/j.metabol.2015.09.017 pii: S0026-0495(15)00271-1.
11. [11] Tahan, V., Canbakan, B., Balci, H., et al. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology 55 (2008), 1433–1438.
12. [12] Castera, L., Vilgrain, V., Angulo, P., Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 10 (2013), 666–675.
13. [13] Keramida, G., Potts, J., Bush, J., et al. Accumulation of (18)F-FDG in the liver in hepatic steatosis. AJR Am J Roentgenol 203 (2014), 643–648.
14. [14] Hong, S.P., Noh, T.S., Moon, S.H., et al. Hepatic glucose uptake is increased in association with elevated serum γ-glutamyltranspeptidase and triglyceride. Dig Dis Sci 59 (2014), 607–613.
15. [15] Higgins JPT, Green S, (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from www.cochrane-handbook.org.
16. [16] Wells, G.A., Shea, B., Higgins, J.P., Sterne, J., Tugwell, P., Reeves, B.C., Checklists of methodological issues for review authors to consider when including non-randomized studies in systematic reviews. Res Synth Methods 4 (2013), 63–77.
17. [17] Greenland, S., Variance estimators for attributable fraction estimates consistent in both large strata and sparse data. Stat Med 6 (1987), 701–708.
18. [18] Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
19. [19] Furukawa, T.A., Guyatt, G.H., Griffith, L.E., Can we individualize the ’number needed to treat’? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol 31 (2002), 72–76.
20. [20] Egger, M., Smith, G.D., Phillips, A.N., Meta-analysis: principles and procedures. BMJ 315 (1997), 1533–1537.
21. [21] Jepsen, P., Vilstrup, H., Mellemkjaer, L., et al. Prognosis of patients with a diagnosis of fatty liver—a registry-based cohort study. Hepatogastroenterology 50 (2003), 2101–2104.
22. [22] Targher, G., Bertolini, L., Rodella, S., et al. Non-alcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30 (2007), 2119–2121.
23. [23] Hamaguchi, M., Kojima, T., Takeda, N., et al. Non-alcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 13 (2007), 1579–1584.
24. [24] Haring, R., Wallaschofski, H., Nauck, M., et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyltranspeptidase levels. Hepatology 50 (2009), 1403–1411.
25. [25] Adams, L.A., Harmsen, S., St Sauver, J.L., et al. Non-alcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol 105 (2010), 1567–1573.
26. [26] Lazo, M., Hernaez, R., Bonekamp, S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ, 343, 2011, d6891.
27. [27] Zhou, Y.J., Li, Y.Y., Nie, Y.Q., et al. Natural course of non-alcoholic fatty liver disease in southern China: a prospective cohort study. J Dig Dis 13 (2012), 153–160.
28. [28] El Azeem, H.A., Khalek, E.S.A., El-Akabawy, H., et al. Association between non-alcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc 25 (2013), 239–246.
29. [29] Pisto, P., Santaniemi, M., Bloigu, R., Ukkola, O., Kesäniemi, Y.A., Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open, 4, 2014, e004973.
30. [30] Pickhardt, P.J., Hahn, L., Muñoz del Rio, A., et al. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. AJR Am J Roentgenol 202 (2014), 752–758.
31. [31] Wong, V.W., Wong, G.L., Yeung, J.C., et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology 63 (2016), 754–763.
32. [32] Moon, S.H., Noh, T.S., Cho, Y.S., et al. Association between non-alcoholic fatty liver disease and carotid artery inflammation evaluated by 18F-fluoro-deoxyglucose positron emission tomography. Angiology 66 (2015), 472–480.
33. [33] Ekstedt, M., Hagström, H., Nasr, P., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
34. [34] Emre, A., Terzi, S., Celiker, E., et al. Impact of non-alcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol 116 (2015), 1810–1814.
35. [35] Zeb, I., Li, D., Budoff, M.J., Katz, R., et al. Non-alcoholic fatty liver disease and incident cardiac events: The Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 67 (2016), 1965–1966.
36. [36] Fracanzani, A.L., Tiraboschi, S., Pisano, G., et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis 246 (2016), 208–213.
37. [37] Kim, D., Kim, W.R., Kim, H.J., et al. Association between non-invasive fibrosis markers and mortality among adults with non-alcoholic fatty liver disease in the United States. Hepatology 57 (2013), 1357–1365.
38. [38] Ghouri, N., Preiss, D., Sattar, N., Liver enzymes, non-alcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 52 (2010), 1156–1161.
39. [39] Musso, G., Gambino, R., Cassader, M., et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43 (2011), 617–649.
40. [40] Lu, H., Liu, H., Zou, L., Luo, S., Sun, L., Independent association between non-alcoholic fatty liver disease and cardiovascular disease: a systematic review and meta-analysis. Int J Endocrinol, 2013, 2013, 124958.
41. [41] Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes. Hepatology, 2015, 10.1002/hep.28431 [Epub ahead of print].
42. [42] Stepanova, M., Younossi, Z.M., Independent association between non-alcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 10 (2012), 646–650.
43. [43] Younossi, Z.M., Otgonsuren, M., Venkatesan, C., et al. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 62 (2013), 352–360.
44. [44] Wong, V.W., Wong, G.L., Yip, G.W., et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60 (2011), 1721–1727.
45. [45] Ekstedt, M., Franzén, L.E., Mathiesen, U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006), 865–873.
46. [46] Soderberg, C., Stål, P., Askling, J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51 (2010), 595–602.
47. [47] Matteoni, C.A., Younossi, Z.M., Gramlich, T., et al. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999), 1413–1419.
48. [48] Rafiq, N., Bai, C., Fang, Y., et al. Long-term follow-up of patients with non-alcoholic fatty liver. Clin Gastroenterol Hepatol 7 (2009), 234–738.
49. [49] Adams, L.A., Lymp, J.F., St Sauver, J., et al. The natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005), 113–121.
50. [50] Angulo, P., Kleiner, D.E., Dam-Larsen, S., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with non-alcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397.
51. [51] Byrne, C.D., Targher, G., Ectopic fat, insulin resistance, and non-alcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 34 (2014), 1155–1161.
52. [52] VanWagner, L.B., Wilcox, J.E., Colangelo, L.A., et al. Association of non-alcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 62 (2015), 773–783.
53. [53] Targher, G., Valbusa, F., Bonapace, S., et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One, 8, 2013, e57183.
54. [54] Mantovani, A., Pernigo, M., Bergamini, C., et al. Heart valve calcification in patients with type 2 diabetes and non-alcoholic fatty liver disease. Metabolism 64 (2015), 879–887.
55. [55] Lonardo, A., Ballestri, S., Targher, G., et al. Diagnosis and management of cardiovascular risk in non-alcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 9 (2015), 629–650.
56. [56] Singh, S., Allen, A.M., Wang, Z., et al. Fibrosis progression in non-alcoholic fatty liver vs. non-alcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654.